Barclays
CNTX icon

Barclays’s Context Therapeutics CNTX Stock Holding History

Barclays’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.2K Buy
+27,504
New +$55.8K ﹤0.01% 4636
2025
Q4 		– Sell
-167
Closed -$162 – 5306
2025
Q3 		$162 Buy
+167
New +$135 ﹤0.01% 5251

Other funds holding CNTX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Barclays's CNTX Position: Q2 2026 in Review

Barclays opened a new position in Context Therapeutics (CNTX) in Q2 2026: 27,504 shares worth $15.2K. The stake represents ﹤0.01% of the portfolio and ranks #4636 among its holdings. This is a return to the name: Barclays previously reported a position in CNTX as recently as Q3 2025.

Barclays first reported a position in CNTX in Q3 2025 and has held it in 2 quarters since. 79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • Barclays held 27,504 shares of Context Therapeutics worth $15.2K as of Q2 2026.
  • Context Therapeutics was a new Barclays position in Q2 2026.
  • Context Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4636 holding.
  • Barclays first reported a position in Context Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.